Chemotherapy Resistance and Sensitivity Testing in Lung Tumors
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Tumor size
研究概览
简要总结
The purpose of this study is to screen chemotherapy drugs currently used to treat lung cancer and determine the most effective treatment based on results of chemo sensitivity testing on the patients own cancer cells in the laboratory. The results of this screening will not influence the patients treatment.
详细描述
The chemosensitivity assay will be performed on tissue obtained during the diagnostic fine needle aspiration, core biopsy, or excisional biopsy of the lung lesion. Cancer cells (Bulk of tumor) and Cancer Stem Cells (CSCs) will be isolated and expanded in the laboratory.
The drug screening assay will be used to evaluate the response of the CSCs and of the cancer cells to the various chemotherapy regimens.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •suspected or confirmed diagnosis of lung cancer
- •undergoing a fine needle aspiration, core biopsy, or excisional biopsy for diagnosis.
- •Chemotherapy must be clinically indicated for treatment of the patient's qualifying disease
- •Patient must be at least 18 years of age
- •Patient must have signed an IRB approved informed consent form for the data collection study prior to entry of data into the enrollment form in the database.
排除标准
- •Patient pathology shows benign pathology for sample submitted
- •Patient is not indicated to receive chemotherapy for their disease
结局指标
主要结局
Tumor size
时间窗: 3 months
Tumor response will be evaluated (progression/regression) by CT scan at 3 months from therapy start. Clinical response to chemotherapy of lung cancer tumor cells versus lung cancer stem cells to standard of care chemo drugs will be evaluated and correlated to predicted drug by ex vivo assay.
次要结局
未报告次要终点
研究者
Pier Paolo Claudio, M.D., Ph.D.
Associate Professor of Biochemistry and Microbiology
Marshall University